nach oben

Erschienen in:

01.01.2017 | Case report

Ceritinib/crizotinib

Development of drug resistance: case report

Einloggen, um Zugang zu erhalten

Author Information

An event is serious (FDA MedWatch definition) when the patient outcome is:

…

Levacq D, et al. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors. Lung Cancer 102: 38-41, Dec 2016. Available from: URL: http://doi.org/10.1016/j.lungcan.2016.10.012 - BelgiumCrossRefPubMed

Titel: Ceritinib/crizotinib
Development of drug resistance: case report
Publikationsdatum: 01.01.2017
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-017-24448-5